نتائج البحث - Insa Gathmann

  • يعرض 1 - 19 نتائج من 19
تنقيح النتائج
  1. 1
    Population pharmacokinetics of imatinib mesylate in patients with chronic‐phase chronic myeloid leukaemia: results of a phase III study

    Population pharmacokinetics of imatinib mesylate in patients with chronic‐phase chronic myeloid leukaemia: results of a phase III study حسب Heinz Schmidli, Bin Peng, G‐J. Riviere, Renaud Capdeville, Martee L. Hensley, Insa Gathmann, Ann E. Bolton, Amy Racine-Poon

    منشور في 2005
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Randomized Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in Treatment of MultidrugResistant Falciparum Malaria

    Randomized Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in Treatment of MultidrugResistant Falciparum Malaria حسب Michèle van Vugt, A Brockman, B Gemperli, C. Luxemburger, Insa Gathmann, C Royce, Thra Slight, S Looareesuwan, Nicholas J. White, François Nosten

    منشور في 1998
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

    Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study حسب Richard A. Larson, Brian J. Druker, François Guilhot, Stephen G. O’Brien, Gilles J. Riviere, Tillmann Krahnke, Insa Gathmann, Yanfeng Wang

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1–5 years

    Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1–5 years حسب Christoph Hatz, Salim Abdulla, Robert Mull, David Schellenberg, David Schellenberg, Insa Gathmann, Pascience Kibatala, Hans‐Peter Beck, Marcel Tanner, Catherine Royce

    منشور في 1998
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria.

    Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. حسب Michèle van Vugt, Polrat Wilairatana, B Gemperli, Insa Gathmann, L Phaipun, A Brockman, C. Luxemburger, Nicholas J. White, François Nosten, S Looareesuwan

    منشور في 1999
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial

    Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial حسب François Guilhot, Timothy P. Hughes, Jorge E. Cortés, Brian J. Druker, Michele Baccarani, Insa Gathmann, Michael Hayes, Camille Granvil, Y. Lynn Wang

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Treatment of African Children with Uncomplicated Falciparum Malaria with a New Antimalarial Drug, CGP 56697

    Treatment of African Children with Uncomplicated Falciparum Malaria with a New Antimalarial Drug, CGP 56697 حسب Lorenz von Seidlein, Shabbar Jaffar, Margaret Pinder, Michelle E. K. Haywood, Georges Snounou, Beatrice M. Gemperli, Insa Gathmann, Catherine Royce, Brian Greenwood

    منشور في 1997
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

    Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia حسب Timothy P. Hughes, Jaspal Kaeda, Susan Branford, Zbigniew Rudzki, Andreas Hochhaus, Martee L. Hensley, Insa Gathmann, Ann E. Bolton, Iris C. van Hoomissen, John M. Goldman, Jerald P. Radich

    منشور في 2003
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children.

    A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children. حسب Lorenz von Seidlein, Kalifa Bojang, Peter B. Jones, Shabbar Jaffar, Margaret Pinder, Stephen Obaro, T Doherty, Michelle E. K. Haywood, Georges Snounou, B Gemperli, Insa Gathmann, C Royce, K McAdam, B Greenwood

    منشور في 1998
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

    Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase حسب Susan Branford, Zbigniew Rudzki, Andrew Harper, Andrew Grigg, K Taylor, Simon Durrant, Chris Arthur, Peter Browett, Anthony P. Schwarer, Dávid Ma, John F. Seymour, Kenneth F. Bradstock, David Joske, Kevin Lynch, Insa Gathmann, Timothy P. Hughes

    منشور في 2003
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cells

    The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cells حسب Michael W. Deininger, Jorge E. Cortés, Ron Paquette, Byung Park, Andreas Hochhaus, Michele Baccarani, Richard M. Stone, Thomas Fischer, Hagop M. Kantarjian, Dietger Niederwieser, Carlo Gambacorti‐Passerini, Charlene So, Insa Gathmann, John M. Goldman, Douglas P. Smith, Brian J. Druker, François Guilhot

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

    A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias حسب Oliver G. Ottmann, Brian J. Druker, Charles L. Sawyers, John M. Goldman, J Reiffers, Richard T. Silver, S Tura, Thomas Fischer, Michael W. Deininger, Charles A. Schiffer, Michele Baccarani, Aloïs Gratwohl, Andreas Hochhaus, Dieter Hoelzer, Sofia Fernandes‐Reese, Insa Gathmann, Renaud Capdeville, Stephen G. O’Brien

    منشور في 2002
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial

    Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial حسب Nikolaus Jahn, Nikolaus Jahn, Maral Saadati, Lars Bullinger, Richard A. Larson, Tiziana Ottone, Sergio Amadori, Thomas W. Prior, Joseph Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Céline Pallaud, Insa Gathmann, Julia Krzykalla, Axel Benner, Clara D. Bloomfield, Christian Thiede, Richard M. Stone, Hartmut Döhner, Konstanze Döhner

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

    Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia حسب Stephen G. O’Brien, François Guilhot, Richard A. Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J. Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy P. Hughes, Klaus Lechner, Johan Lanng Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John D. Shepherd, Bengt Simonsson, Aloïs Gratwohl, John M. Goldman, Hagop M. Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E. Bolton, Renaud Capdeville, Brian J. Druker

    منشور في 2003
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Relative response of patients with myelodysplastic syndromes and other transfusion‐dependent anaemias to deferasirox (ICL670): a 1‐yr prospective study

    Relative response of patients with myelodysplastic syndromes and other transfusion‐dependent anaemias to deferasirox (ICL670): a 1‐yr prospective study حسب John B. Porter, Renzo Galanello, Giuseppe Saglio, Ellis J. Neufeld, Elliott Vichinsky, Maria Domenica Cappellini, Nancy F. Olivieri, Antonio Piga, Melody J. Cunningham, Denis Soulières, Norbert Gattermann, G Tchernia, Johan Maertens, Patricia J. Giardina, Janet L. Kwiatkowski, Giovanni Quarta, Michael Jeng, Gian Luca Forni, Michael Stadler, Holger Cario, Louisette Debusscher, Matteo Giovanni Della Porta, Mario Cazzola, Peter L. Greenberg, Giuliana Alimena, B. Rabault, Insa Gathmann, J. Ford, Daniele Alberti, Christian Rosé

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

    Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results حسب Frank G. Rücker, Ling Du, Tamara J. Luck, Axel Benner, Julia Krzykalla, Insa Gathmann, Maria Teresa Voso, Sergio Amadori, Thomas W. Prior, Joseph Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Lynn Savoie, Jorge Sierra, Céline Pallaud, Miguel Á. Sanz, Joop H. Jansen, Dietger Niederwieser, Thomas Fischer, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Lars Bullinger, Richard A. Larson, Clara D. Bloomfield, Richard M. Stone, Hartmut Döhner, Christian Thiede, Konstanze Döhner

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

    Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia حسب Brian J. Druker, François Guilhot, Stephen G. O’Brien, Insa Gathmann, Hagop M. Kantarjian, Norbert Gattermann, Michael W. Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy P. Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, John D. Shepherd, Giuseppe Saglio, Aloïs Gratwohl, Johan Lanng Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak, Richard A. Larson

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

    Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial حسب Richard A. Larson, Sumithra J. Mandrekar, Lucas J. Huebner, Ben L. Sanford, Kristina Laumann, Susan M. Geyer, Clara D. Bloomfield, Christian Thiede, Thomas W. Prior, Konstanze Döhner, Guido Marcucci, Maria Teresa Voso, Rebecca B. Klisovic, Ilene Galinsky, Andrew H. Wei, Jorge Sierra, Miguel Á. Sanz, Joseph Brandwein, Théo de Witte, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Jürgen Krauter, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Insa Gathmann, Hartmut Döhner, Richard M. Stone

    منشور في 2021
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

    Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia حسب Konstanze Döhner, Christian Thiede, Nikolaus Jahn, Ekaterina Panina, Agnes Gambietz, Richard A. Larson, Thomas W. Prior, Guido Marcucci, Dan Jones, Jürgen Krauter, Michael Heuser, Maria Teresa Voso, Tiziana Ottone, Josep Nomdedéu, Sumithra J. Mandrekar, Rebecca B. Klisovic, Andrew H. Wei, Jorge Sierra, Miguel Á. Sanz, Joseph Brandwein, Théo de Witte, Joop H. Jansen, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Insa Gathmann, Axel Benner, Céline Pallaud, Richard M. Stone, Hartmut Döhner, Clara D. Bloomfield

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: